- Home
- SLGL vs BLRX Comparison
SLGL vs BLRX Comparison
Compare SLGL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- BLRX
- Stock Information
- Founded
- SLGL 1997
- BLRX 2003
- Country
- SLGL Israel
- BLRX Israel
- Employees
- SLGL N/A
- BLRX N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- BLRX Health Care
- Exchange
- SLGL Nasdaq
- BLRX Nasdaq
- Market Cap
- SLGL 17.0M
- BLRX 17.3M
- IPO Year
- SLGL 2018
- BLRX 2011
- Fundamental
- Price
- SLGL $0.58
- BLRX $3.59
- Analyst Decision
- SLGL Strong Buy
- BLRX Strong Buy
- Analyst Count
- SLGL 2
- BLRX 2
- Target Price
- SLGL $5.00
- BLRX $220.00
- AVG Volume (30 Days)
- SLGL 62.4K
- BLRX 154.8K
- Earning Date
- SLGL 03-12-2025
- BLRX 03-25-2025
- Dividend Yield
- SLGL N/A
- BLRX N/A
- EPS Growth
- SLGL N/A
- BLRX N/A
- EPS
- SLGL N/A
- BLRX N/A
- Revenue
- SLGL $11,707,000.00
- BLRX $21,991,000.00
- Revenue This Year
- SLGL $772.97
- BLRX N/A
- Revenue Next Year
- SLGL N/A
- BLRX N/A
- P/E Ratio
- SLGL N/A
- BLRX N/A
- Revenue Growth
- SLGL 869.93
- BLRX N/A
- 52 Week Low
- SLGL $0.33
- BLRX $3.20
- 52 Week High
- SLGL $1.65
- BLRX $57.60
- Technical
- Relative Strength Index (RSI)
- SLGL 37.73
- BLRX 36.94
- Support Level
- SLGL $0.56
- BLRX $3.26
- Resistance Level
- SLGL $0.61
- BLRX $4.17
- Average True Range (ATR)
- SLGL 0.07
- BLRX 0.28
- MACD
- SLGL -0.01
- BLRX 0.24
- Stochastic Oscillator
- SLGL 12.00
- BLRX 36.26
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.